Financhill
Buy
74

MO Quote, Financials, Valuation and Earnings

Last price:
$58.34
Seasonality move :
3.39%
Day range:
$58.70 - $59.32
52-week range:
$40.65 - $59.67
Dividend yield:
6.79%
P/E ratio:
8.99x
P/S ratio:
4.95x
P/B ratio:
--
Volume:
8.6M
Avg. volume:
8.6M
1-year change:
34.26%
Market cap:
$99.6B
Revenue:
$20.4B
EPS (TTM):
$6.55

MO Analysts' Consensus Rating

The 12 analysts providing 12-month price projections for Altria Group shares anticipate an average target of $56.66, ranging from a low estimate of $42.00 to a high estimate of $73.00. This average target implies a growth of -3.8% compared to the current stock price of $58.90.

Consensus Price Target

$56.66

Highest Price Target

$73.00

Lowest Price Target

$42.00

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Analyst Ratings

6M Ago 1M Ago Current
Buy 3 4 4

Hold 6 7 7

Sell 1 1 1
Consensus Hold Hold Hold

MO Recommendation Trends

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock